title: Modulation of keratinocyte growth factor (KGF) mRNA expression in human dermal fibroblasts grown in monolayer or within a collagen matrix.
abstract: In this study, we analysed the modulation of keratinocyte growth factor (KGF) mRNA expression in human dermal fibroblasts cultured either in monolayer or within a collagen matrix (dermal equivalent). In monolayer cultures, KGF expression by quiescent fibroblasts was stimulated by different growth substances such as serum, epidermal growth factor and basic fibroblast growth factor. Moreover, we demonstrated that the induction of this gene was mediated by at least 2 different signalling pathways involving protein kinase C (PKC) and cAMP. In dermal equivalents, we observed that the collagen matrix negatively modulated KGF mRNA expression. Indeed, among the growth substances used, only the serum slightly stimulated KGF expression. Nevertheless, as in monolayers, this induction involved at least PKC and cAMP signalling pathways. As the collagen matrix can modulate fibroblast growth, we also studied KGF expression in growing fibroblasts from either monolayer cultures or dermal equivalents. We then showed that this collagen matrix negatively influenced KGF expression independently of the proliferative state of fibroblasts. All these results underline the fact that KGF mRNA expression by human dermal fibroblasts is induced by different substances; however this expression can be modulated by fibroblast-matrix interactions.
authors: Unité INSERM 312, Laboratoire de Dermatologie, Hopital Saint Louis, Paris, France.
authors: R
authors: R
authors: Le Panse
authors: B
authors: B
authors: Bouchard
authors: C
authors: C
authors: Lebreton
authors: B
authors: B
authors: Coulomb
mesh_terms: D000293:Adolescent; D000328:Adult; D001940:Breast; D002455:Cell Division; D002478:Cells, Cultured; D002772:Cholera Toxin / Q000494:pharmacology; D017077:Culture Media, Conditioned; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D051526:Fibroblast Growth Factor 10; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006133:Growth Substances / Q000096:biosynthesis*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D015603:Keratinocytes; D008301:Maleimides / Q000494:pharmacology; D008875:Middle Aged; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000096:biosynthesis*; D015398:Signal Transduction; D012867:Skin / Q000166:cytology / Q000378:metabolism*; D013518:Surgery, Plastic; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D017077:Culture Media, Conditioned; D004791:Enzyme Inhibitors; C496453:FGF7 protein, human; D051526:Fibroblast Growth Factor 10; D006133:Growth Substances; D007211:Indoles; D008301:Maleimides; D012333:RNA, Messenger; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor; D002772:Cholera Toxin; D011493:Protein Kinase C; C070515:bisindolylmaleimide I; D013755:Tetradecanoylphorbol Acetate